| Identification | Back Directory | [Name]
B014 | [CAS]
1215208-59-5 | [Synonyms]
B014
MPT0B014
MPT0B014 >=98% (HPLC)
6-Quinolinyl(3,4,5-trimethoxyphenyl)methanone | [Molecular Formula]
C19H17NO4 | [MOL File]
1215208-59-5.mol | [Molecular Weight]
323.34 |
| Chemical Properties | Back Directory | [Boiling point ]
513.5±50.0 °C(Predicted) | [density ]
1.211±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble5mg/mL, clear (warmed) | [form ]
powder | [pka]
3.84±0.10(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
MPT0B014 is a tubulin polymerization inhibitor. MPT0B014 induces cancer cell apoptosis. MPT0B014 can be used for the research of cancer[1]. | [in vivo]
The combination of MPT0B014 (100 mg/kg; i.v./i.p.; daily for 25 days) and 25 mg/kg Erlotinib (HY-50896) significantly improves A549 tumor inhibition in mice[1]. | Animal Model: | Nude athymic mice, A549 xenografts[1] | | Dosage: | 100 mg/kg alone or in combination with 25 mg/kg Erlotinib (HY-50896) | | Administration: | i.v./i.p., daily for 25 days | | Result: | The combined treatment resulted in more significant tumor growth delay (28%) compared with treatment alone (7%). The combination produced significantly higher anti-tumor activity. The growth of A549 cancer cell xenografts was suppressed by 11, 21 and 49% (tumor growth inhibition) after treatment with MPT0B014, Erlotinib and MPT0B014 plus Erlotinib, respectively.
|
| [storage]
Store at -20°C | [References]
[1] Tsai AC, et al. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells. Br J Pharmacol. 2014 Jan;171(1):122-33. DOI:10.1111/bph.12427 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|